Jiuzhou Wang
About
Jiuzhou Wang is a scholar working on Oncology, Reproductive Medicine and Pulmonary and Respiratory Medicine.
According to data from OpenAlex, Jiuzhou Wang has authored 33 papers receiving a total of 1.0k indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Oncology, 14 papers in Reproductive Medicine and 13 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Jiuzhou Wang's work include Ovarian cancer diagnosis and treatment (14 papers), Advanced Breast Cancer Therapies (6 papers) and HER2/EGFR in Cancer Research (6 papers). Jiuzhou Wang is often cited by papers focused on Ovarian cancer diagnosis and treatment (14 papers), Advanced Breast Cancer Therapies (6 papers) and HER2/EGFR in Cancer Research (6 papers). Jiuzhou Wang collaborates with scholars based in United States, Spain and Italy. Jiuzhou Wang's co-authors include Marc G. Genton, Ana Oaknin, Ursula A. Matulonis, Michael Method, Julie D. Horan, Margaret A. Foley, Piotr Serwatowski, Karen Kelly, Mary O’Brien and Lucio Crinò and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.
In The Last Decade
Jiuzhou Wang
32 papers receiving 984 citations
Hit Papers
Peers
Jiuzhou Wang
Akihiro Hirakawa Japan
Pralay Mukhopadhyay United States
Bronislava M. Sigal United States
Claire Amos United Kingdom
Geoffrey Kim United States
Jana Barinoff Germany
Coraline Dubot France
Fabian Zohren United States
Bettzy Stephen United States
Oana Petrenciuc United States
Citations per year, relative to Jiuzhou Wang Jiuzhou Wang (= 1×)
peers
Akihiro Hirakawa
Countries citing papers authored by Jiuzhou Wang
Since
Specialization
Citations
This map shows the geographic impact of Jiuzhou Wang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jiuzhou Wang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jiuzhou Wang more than expected).
Fields of papers citing papers by Jiuzhou Wang
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Jiuzhou Wang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jiuzhou Wang. The network helps show where Jiuzhou Wang may publish in the future.
Co-authorship network of co-authors of Jiuzhou Wang
This figure shows the co-authorship network connecting the top 25 collaborators of Jiuzhou Wang. A scholar is included among the top collaborators of Jiuzhou Wang based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jiuzhou Wang. Jiuzhou Wang is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Wang, Jiuzhou, et al.. (2024). Phototherapy Alters the Plasma Metabolite Profile in Infants Born Preterm with Hyperbilirubinemia. The Journal of Pediatrics. 274. 114175–114175.
2.
Wang, Jiuzhou & Eric F. Lock. (2024). Multiple augmented reduced rank regression for pan-cancer analysis. Biometrics. 80(1).
3.
Wang, Jiuzhou & Sandra E. Safo. (2024). Deep IDA: a deep learning approach for integrative discriminant analysis of multi-omics data with feature ranking—an application to COVID-19. Bioinformatics Advances. 4(1). vbae060–vbae060.
4.
Matulonis, Ursula A., Domenica Lorusso, Ana Oaknin, et al.. (2023). Reply to Z.R. McCaw et al. Journal of Clinical Oncology. 41(29). 4705–4706.
5.
Matulonis, Ursula A., Domenica Lorusso, Ana Oaknin, et al.. (2023). Efficacy and Safety of Mirvetuximab Soravtansine in Patients With Platinum-Resistant Ovarian Cancer With High Folate Receptor Alpha Expression: Results From the SORAYA Study. Obstetrical & Gynecological Survey. 78(6). 343–344.
6.
Matulonis, Ursula A., Domenica Lorusso, Ana Oaknin, et al.. (2023). Efficacy and Safety of Mirvetuximab Soravtansine in Patients With Platinum-Resistant Ovarian Cancer With High Folate Receptor Alpha Expression: Results From the SORAYA Study. Journal of Clinical Oncology. 41(13). 2436–2445.
7.
Gilbert, Lucy, Ana Oaknin, Ursula A. Matulonis, et al.. (2023). Safety and efficacy of mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients with platinum-resistant ovarian cancer. Gynecologic Oncology. 170. 241–247.
8.
Oaknin, Ana, Domenica Lorusso, Amit M. Oza, et al.. (2022). 2022-RA-660-ESGO Characterization of extended treatment benefit from three phase 1 and 3 clinical trials examining patients with folate receptor alpha-positive recurrent ovarian cancer treated with single-agent mirvetuximab soravtansine. International Journal of Gynecological Cancer. 32. A251–A252.
9.
O’Malley, David M., Ana Oaknin, Ursula A. Matulonis, et al.. (2022). O011/#496 Mirvetuximab soravtansine and bevacizumab in folate receptor αlpha-positive ovarian cancer: efficacy in patients with and without prior bevacizumab. A7.2–A8.
10.
Moore, Kathleen N., Gottfried E. Konecny, Lainie P. Martin, et al.. (2022). MIRASOL: A randomized, open-label, phase 3 study of mirvetuximab soravtansine vs. investigator’s choice of chemotherapy in advanced high-grade epithelial ovarian, primary peritoneal, or fallopian tube cancers with high folate-alpha (FRα) expression (297). Gynecologic Oncology. 166. S156–S157.
11.
O’Malley, David M., Ana Oaknin, Ursula A. Matulonis, et al.. (2021). Mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients (pts) with platinum-agnostic ovarian cancer: Final analysis.. Journal of Clinical Oncology. 39(15_suppl). 5504–5504.
12.
Dong, Gaohong, Bo Huang, Duolao Wang, et al.. (2020). Adjusting win statistics for dependent censoring. Pharmaceutical Statistics. 20(3). 440–450.
13.
Dong, Gaohong, Lu Mao, Bo Huang, et al.. (2020). The inverse-probability-of-censoring weighting (IPCW) adjusted win ratio statistic: an unbiased estimator in the presence of independent censoring. Journal of Biopharmaceutical Statistics. 30(5). 882–899.
14.
Daver, Naval, Eunice S. Wang, Kendra Sweet, et al.. (2020). A phase Ib/II study of the CD123-targeting antibody-drug conjugate IMGN632 as monotherapy or in combination with venetoclax and/or azacitidine for patients with CD123-positive acute myeloid leukemia.. Journal of Clinical Oncology. 38(15_suppl). TPS7564–TPS7564.
15.
Moore, Kathleen N., Toon Van Gorp, Jiuzhou Wang, Brooke Esteves, & Patrick A. Zweidler‐McKay. (2020). MIRASOL (GOG 3045/ENGOT OV-55): A randomized, open-label, phase III study of mirvetuximab soravtansine versus investigator’s choice of chemotherapy in advanced high-grade epithelial ovarian, primary peritoneal, or fallopian tube cancers with high folate-alpha (FRα) expression.. Journal of Clinical Oncology. 38(15_suppl). TPS6103–TPS6103.
16.
Han, Wei, et al.. (2019). Comparative analysis of cellular expression pattern of schizophrenia risk genes in human versus mouse cortex. Cell & Bioscience. 9(1). 89–89.
17.
Jakacki, Regina I., Margaret A. Foley, Julie D. Horan, et al.. (2016). Single-agent erlotinib versus oral etoposide in patients with recurrent or refractory pediatric ependymoma: a randomized open-label study. Journal of Neuro-Oncology. 129(1). 131–138.
18.
Kelly, Karen, Nasser K. Altorki, Wilfried Eberhardt, et al.. (2014). A randomized, double-blind phase 3 trial of adjuvant erlotinib (E) versus placebo (P) following complete tumor resection with or without adjuvant chemotherapy in patients (pts) with stage IB-IIIA EGFR positive (IHC/FISH) non-small cell lung cancer (NSCLC): RADIANT results.. Journal of Clinical Oncology. 32(15_suppl). 7501–7501.
19.
O’Brien, Mary, Wilfried Eberhardt, Nasser K. Altorki, et al.. (2014). Analysis of treatment duration and safety of adjuvant erlotinib (E) versus placebo (P) after surgery in patients (pts) with non-small cell lung cancer (NSCLC): RADIANT trial.. Journal of Clinical Oncology. 32(15_suppl). 7535–7535.
20.
Wang, Jiuzhou, et al.. (2002). A SKEW-SYMMETRIC REPRESENTATION OF MULTIVARIATE DISTRIBUTIONS. NCSU Libraries Repository (North Carolina State University Libraries).
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Akihiro Hirakawa Breakdown of academic impact, for papers by Pralay Mukhopadhyay Breakdown of academic impact, for papers by Bronislava M. Sigal Breakdown of academic impact, for papers by Claire Amos Breakdown of academic impact, for papers by Geoffrey Kim Breakdown of academic impact, for papers by Jana Barinoff Breakdown of academic impact, for papers by Coraline Dubot Breakdown of academic impact, for papers by Fabian Zohren Breakdown of academic impact, for papers by Bettzy Stephen Breakdown of academic impact, for papers by Oana Petrenciuc